Akero Therapeutics Stock Income Statements

Akero Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Akero Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30

operating expenses:
research and development	69,254,000	69,567,000	69,293,000	72,232,000	55,322,000	50,650,000	53,392,000	38,634,000	27,985,000	21,787,000	18,320,000	25,087,000	21,363,000	20,514,000	27,711,000	19,470,000	23,976,000	10,602,000	25,709,000	17,379,000	13,037,000	8,791,000	13,138,000	13,885,000	5,960,000
general and administrative	11,619,000	11,315,000	8,732,000	9,471,000	10,419,000	9,304,000	8,481,000	7,981,000	7,644,000	6,966,000	7,100,000	11,004,000	6,231,000	5,537,000	4,728,000	4,883,000	4,990,000	4,526,000	4,074,000	4,159,000	3,417,000	3,588,000	3,083,000	2,424,000	1,649,000
total operating expenses	80,873,000	80,882,000	78,025,000	81,703,000	65,741,000	59,954,000	61,873,000	46,615,000	35,629,000	28,753,000	25,420,000	36,091,000	27,594,000	26,051,000	32,439,000	24,353,000	28,966,000	15,128,000	29,783,000	21,538,000	16,454,000	12,379,000	16,221,000	16,309,000	7,609,000
income from operations	-80,873,000	-80,882,000	-78,025,000	-81,703,000	-65,741,000	-59,954,000	-61,873,000	-46,615,000	-35,629,000	-28,753,000	-25,420,000	-36,091,000	-27,594,000	-26,051,000	-32,439,000	-24,353,000	-28,966,000	-15,128,000	-29,783,000	-21,538,000	-16,454,000	-12,379,000	-16,221,000	-16,309,000
yoy	23.02%	34.91%	26.11%	75.27%	84.52%	108.51%	143.40%	29.16%	29.12%	10.37%	-21.64%	48.20%	-4.74%	72.20%	8.92%	13.07%	76.04%	22.21%	83.61%	32.06%
qoq	-0.01%	3.66%	-4.50%	24.28%	9.65%	-3.10%	32.73%	30.83%	23.91%	13.11%	-29.57%	30.79%	5.92%	-19.69%	33.20%	-15.93%	91.47%	-49.21%	38.28%	30.90%	32.92%	-23.69%	-0.54%
operating margin %
interest expense	-1,172,000	-1,154,000	-1,200,000	-1,246,000	-1,231,000	-991,000	-897,000	-888,000	-857,000	-457,000	-362,000	-324,000	-53,000
interest and other income	11,540,000	11,311,000	9,201,000	10,244,000	10,985,000	7,601,000
net income	-70,505,000	-70,725,000	-70,024,000	-72,705,000	-55,987,000	-53,344,000	-55,186,000	-39,659,000	-31,083,000	-25,831,000	-23,059,000	-35,542,000	-27,403,000	-26,029,000	-32,424,000	-24,330,000	-28,933,000	-15,090,000	-29,711,000	-21,403,000	-16,207,000	-11,886,000
yoy	25.93%	32.58%	26.89%	83.33%	80.12%	106.51%	139.33%	11.58%	13.43%	-0.76%	-28.88%	46.08%	-5.29%	72.49%	9.13%	13.68%	78.52%	26.96%
qoq	-0.31%	1.00%	-3.69%	29.86%	4.95%	-3.34%	39.15%	27.59%	20.33%	12.02%	-35.12%	29.70%	5.28%	-19.72%	33.27%	-15.91%	91.74%	-49.21%	38.82%	32.06%	36.35%
net income margin %
net unrealized gain on marketable securities	-97,000	137,000	-1,155,000	2,364,000			776,000	-255,000	-272,000
comprehensive loss	-70,602,000	-70,588,000	-71,179,000	-70,341,000	-56,169,000	-53,693,000	-54,410,000	-39,914,000	-31,355,000	-25,847,000	-23,022,000	-35,539,000	-27,376,000	-26,032,000	-32,434,000	-24,338,000	-28,940,000	-15,089,000	-29,730,000	-21,477,000	-16,162,000	-11,835,000
net income per common share, basic and diluted	-860	-900	-990	-1,050	-810	-900	-1,020	-710	-600	-550	-420	-920	-770	-740	-930	-700	-830	-430	-890	-630	-570	-420
weighted-average number of shares used in computing net income per common share, basic and diluted	81,721,387,000	78,656,629,000	67,136,772,000	69,442,136,000	69,160,484,000	59,307,759,000	52,568,159,000	55,613,120,000	51,867,854,000	46,944,059,000	38,984,772,000	38,663,469,000	35,383,685,000	35,005,501,000	34,827,385,000	34,862,116,000	34,814,631,000	34,744,275,000	31,463,248,000	34,002,769,000	28,602,976,000	28,499,475,000
net unrealized loss on marketable securities					-182,000	-349,000
other income							4,156,500	7,844,000	5,403,000	3,379,000	2,723,000	873,000	244,000	22,000	15,000	23,000	33,000	38,000					610,000	755,000	381,000
net unrealized loss on short-term marketable securities										-16,000
net unrealized gain on short-term marketable securities											37,000	3,000	27,000	-3,000	-10,000	-8,000						51,000
other income:
interest income																						493,000
total other income																			218,750	135,000	247,000	493,000	610,000	755,000	381,000
other incomes
other income, net:
change in fair value of preferred stock tranche obligation
change in fair value of anti-dilution right liability
net income and comprehensive loss																							-7,036,000	-15,554,000
accretion of redeemable convertible preferred stock to redemption value
net income attributable to common stockholders																							-15,611,000	-15,554,000	-7,228,000
net income per share																							-0.24	-0.56	-2.21
weighted-average number of shares used in computing net income per share attributable to common stockholders, basic and diluted																							15,070,728	28,024,779	3,268,390

We provide you with 20 years income statements for Akero Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Akero Therapeutics stock. Explore the full financial landscape of Akero Therapeutics stock with our expertly curated income statements.

The information provided in this report about Akero Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.